CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if it is possible to give CPI-613 with the drug
Bendamustine for 2 days every 28 days without causing severe side effects. In addition, this
study will also test the safety of CPI-613 when given in combination with Bendamustine.